Drug Profile
SPL 108
Alternative Names: SPL 108Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Splash Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase Unknown Prostate cancer
- No development reported Brain cancer; Breast cancer; Cancer; Endometrial cancer; Liver cancer; Macular degeneration; Rheumatoid arthritis
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Brain-cancer(Combination therapy) in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Breast-cancer(Combination therapy) in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Endometrial-cancer(Combination therapy) in USA